Hong, Min Hee
Yonsei University · Severance Hospital · Yonsei Cancer Hospital
3 papers on CoChatORCID 0000-0003-3490-2195
Most cited papers
- Verified
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., et al. (2020) · Cancer Discovery
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 297
- Verified
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
Harding, J. J., Moreno, V., Bang, Y.-J., Hong, M. H., Patnaik, A., Trigo, J., Szpurka, A. M., Yamamoto, N., Doi, T., Fu, S., et al. (2021) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 161
- Verified
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC
Ahn, M.-J., Lisberg, A., Goto, Y., Sands, J., Hong, M. H., Paz-Ares, L., Pons-Tostivint, E., Pérol, M., Felip, E., Sugawara, S., et al. (2025) · Journal of Thoracic Oncology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 66
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free